Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04610658 · ClinicalTrials.gov registry record · Phase 1
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04610658 is a Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 9 participants.
The verdict
NCT04610658, a Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-line, platinum-based chemotherapy
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Lurbinectedin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2023-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04610658
The ClinicalTrials.gov registry entry for NCT04610658 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04610658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04610658 about?
NCT04610658 is a clinical study titled "Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC". This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-li...
What is the current status of trial NCT04610658?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-11-23. Estimated completion is 2023-03-24.
What interventions are being tested in trial NCT04610658?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT04610658?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.